Disease burden of biliary tract cancer in 204 countries and territories, 1990-2021: A comprehensive demographic analysis of the Global Burden of Disease Study 2021

被引：0

作者：

Sun, Xuheng ^{[1
]}

Liu, Jiangmei ^{[2
]}

Zhang, Wei ^{[3
]}

Wang, Yijun ^{[1
]}

Jiang, Yan ^{[4
]}

Wang, Lijun ^{[2
]}

Zou, Yixin ^{[3
]}

Xiao, Yuxuan ^{[3
]}

Xiang, Yongbing ^{[3
]}

Li, Maolan ^{[1
,5
,6
]}

Zhou, Maigeng ^{[2
]}

Liu, Yingbin ^{[1
,5
,6
,7
,8
]}

机构：

[1] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Biliary & Pancreat Surg, 160 Pujian Rd, Shanghai 200120, Peoples R China

[2] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pre, Beijing 100050, Peoples R China

[3] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Dept Epidemiol,Sch Med, Shanghai 200120, Peoples R China

[4] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Med Affairs, Shanghai 200120, Peoples R China

[5] Shanghai Jiao Tong Univ, Renji Hosp, Dept Gen Surg, Jiading Branch,Sch Med, Shanghai 201800, Peoples R China

[6] Shanghai Key Lab Syst Regulat & Clin Translat Canc, Shanghai 200127, Peoples R China

[7] Shanghai Canc Inst, State Key Lab Syst Med Canc, Shanghai 200127, Peoples R China

[8] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Sch Med, Shanghai 200120, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2024年 / 137卷 / 24期

基金：

中国国家自然科学基金;

关键词：

Biliary tract carcinoma; Global Burden of Disease Study; Incidence; Mortality; Disability-adjusted life-year; Human Development Index; GALLBLADDER CANCER; SYSTEMATIC ANALYSIS; TRENDS; RISK; GALLSTONES; EPIDEMIOLOGY; MORTALITY; SHANGHAI; HISTORY;

D O I：

10.1097/CM9.0000000000003395

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background:Biliary tract carcinomas (BTCs) are relatively rare but lethal primary malignant tumors derived from the biliary tract system. The burden of BTCs varies according to sex, age, region, and country, but limited attention has been paid to the burden of BTCs. We sought to explore the up-to-date data from the Global Burden of Disease Study (GBD) and expand findings by accessing the demographic features of BTC disease burden.Methods:Using the latest data from the GBD 2021, we evaluated and analyzed the distributions and patterns of BTC disease burden in various age groups, sexes, regions, and countries.Results:The number of incident cases, deaths, and disability-adjusted life-years (DALYs) tended to increase and peaked at 216,770 (95% uncertainty interval [UI]: 181,890-245,240), 171,960 (95% UI: 142,350-194,240), and 3,732,100 (95% UI: 3,102,900-4,317,000) person-years, respectively, in 2021. However, the average global age-standardized rates (ASRs) of incident cases, deaths, and DALYs shrunk by -11.46% (95% UI: -21.91 to 3.35%), -24.09% (95% UI: -33.19 to 16.88%), and -26.25% (95% UI: -35.53 to 18.36%), respectively, from 1990 to 2021. Meanwhile, the male/female ratio (male per 100 female) of incidence, deaths, and DALYs changed from 76.40, 75.41, and 74.72 to 86.89, 79.11, and 82.29, respectively. In 2021, the highest number of incident cases, deaths, and DALYs occurred in East Asia. The top three highest incidences, deaths, and DALYs were observed in China, India, and Japan, and the highest ASRs were observed in Chile in 2021. Analysis of the Human Development Index along with disease burden estimates of BTCs also suggests that the burden of the disease is related to the level of comprehensive development of the society.Conclusion:This study provided a comprehensive comparison of differences in the burden of disease across populations and over time, and further presented evidence concerning the formulation of prevention and control policies and etiologic studies for BTCs and proposed logical hypotheses to investigate.

引用

页码：3117 / 3125

页数：9

共 42 条

[1]

Roa J.C., Garcia P., Kapoor V.K., Maithel S.K., Javle M., Koshiol J., Gallbladder cancer, Nat Rev Dis Primers, 8, (2022)

[2]

Shroff R.T., Kennedy E.B., Bachini M., Bekaii-Saab T., Crane C., Edeline J., Et al., Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline, J Clin Oncol, 37, pp. 1015-1027, (2019)

[3]

Vogel A., Bridgewater J., Edeline J., Kelley R.K., Klumpen H.J., Malka D., Et al., Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Ann Oncol, 34, pp. 127-140, (2023)

[4]

Song X., Hu Y., Li Y., Shao R., Liu F., Liu Y., Overview of current targeted therapy in gallbladder cancer, Signal Transduct Target Ther 2020, 5

[5]

Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition) (in Chinese), Chin J Surg, 58, pp. 243-251, (2020)

[6]

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021, Lancet, 403, pp. 2162-2203, (2024)

[7]

Gao S., Yang W.S., Bray F., Va P., Zhang W., Gao J., Et al., Declining rates of hepatocellular carcinoma in urban Shanghai: Incidence trends in 1976-2005, Eur J Epidemiol, 27, pp. 39-46, (2012)

[8]

Clements O., Eliahoo J., Kim J.U., Taylor-Robinson S.D., Khan S.A., Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis, J Hepatol, 72, pp. 95-103, (2020)

[9]

Wang Y., Huang Y., Chase R.C., Li T., Ramai D., Li S., Et al., Global burden of digestive diseases: A systematic analysis of the Global Burden of Diseases Study, 1990 to 2019, Gastroenterology, 165, (2023)

[10]

Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 74, pp. 229-263, (2024)

← 1 2 3 4 5 →